Lifecore Biomedical 주식 (NASDAQ: LFCR)

에 대한 최신 뉴스 Lifecore Biomedical (NASDAQ:LFCR) 주식

Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

LFCR

SPSC

미국 주식 선물이 금요일 아침 (현지 시간 기준) 상승하고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다: 진디엑스 홀딩스(NASDAQ:WGS)는 브라이언 디카이로(Bryan Dechairo)를 COO로 임명했다고 발표했다. 진디엑스 주식은 애프터 마켓에서 2.7% 하락하여 $77.46에 거래되었다.

금요일 주목해야 할 주식: 리소스 커넥션, SPS 커머스, 라이프코어, 진디엑스 및 UDR

XPEV

목요일 아침 (현지 시간 기준) 미국 주식 선물이 상승함에 따라, 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다: 월스트리트는 리소스 커넥션(NASDAQ:RGP)이 시장 마감 후에 1억 3,702만 달러의 매출을 보고할 것으로 예상하고 있다. 이에 따라 리소스 커넥션 주식은 시간외 거래에서 2% 상승한 8.70달러로 거래되었다.

목요일 주목해야 할 주식: 니오, 리 오토, 리소스 커넥션, 샤오펑 및 라이프코어 바이오메디컬

NVDA

CNN 머니 공포와 탐욕 지수가 전체 공포 수준이 약간 완화되었음을 보여주었지만, 이 지수는 화요일에 여전히 &#34;공포&#34; 구역에 머물렀다. 미국 주식은 화요일에 하락세로 마감했으며, 나스닥 종합지수는 세션 중 약 175포인트 하락했다.

2024년 S&amp;P 500 지수 23% 급등, 그러나 탐욕 지수는 &#39;공포&#39; 지역에 머물러

Lifecore Biomedical Inc

Macro Economic Events

Global

Economics

A Group Of Canada Premiers Expected To Meet With President Trump At White House On Wednesday

Official inflation numbers came out yesterday morning, showing an increase across the board. This has stoked fears the Fed may not decrease rates and may have to even increase rates in an already fragile environment.
Pretty much every ticker across the board dipped on the news, while some bounced back a little later. NVDA dropped from $134 to $129 on the news and has since bounced back above $130. But it's barely holding on. The question on traders' minds is "is it time to dip buy NVDA?"
Let's dive into how my PFP system is looking at NVDA and how we're looking to trade it.
<h2 class="wp-block-heading">Options Positioning in NVDA</h2>
Looking at the positional chart below (notional gamma) for NVDA, we can see $130 is a massive level. There are definitely more calls than puts at $130 (blue line) but the largest amount of put gamma (for the February options expiration) is at $130.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1-1024x602.png" alt="" class="wp-image-779371" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131902/echarts-1.png 1310w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
This makes the $130 level the TGS (top gamma strike) and bulls will want to hold this to retain a bullish bias and a modicum of control.
If NVDA can hold and ideally regain some ground, then this favors staying bullish on NVDA, so if you don't have a bullish position, and feel $130 will hold, this is your line in the sand to get long.
On the other side, if we start to close below $130, puts will be mostly in control. This lends itself to more volatility and bears having a greater influence on the price action. Thus, if you want to establish a bearish position, you'd want to see a daily close under $130 to get bearish. We see almost the same fuel at $125 and $120, so those would be our downside targets if we got bearish.
<h2 class="wp-block-heading">Option Flows for NVDA</h2>
As I'm writing this on Wednesday morning, the NVDA option flows are neutral to mildly bearish with traders selling a mild amount of calls (-17M notional deltas) and buying a small amount of puts (-9M notional deltas). This is a very modicum of bearish flows.
Traders simply aren't hitting the gas to buy hand over fist, but they're not establishing seriously bearish positions (yet).
I think a daily close under $130 likely ignites more bearish positions, but this is not the flow I want to see to buy the dip.
<h2 class="wp-block-heading">Price Action in NVDA</h2>
Looking at the chart below, we can see the impulsive selling pre-market from the core inflation print, and a corrective bounce since. This corrective bounce is not the most inspiring, and clearly matches the lackluster buying response in the option flows.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-1024x502.png" alt="" class="wp-image-779370" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-1024x502.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36-1536x753.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12131857/NVDA_2025-02-12_10-05-36.png 1835w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
5-minute NVDA chart
$130 is the TGS, so it's not surprising to see a fair dinkum of price action around there. Regaining $133.5 helps as it would have recovered the CPI losses while losing $130 on a daily closing basis could add fresh technical selling.
<h2 class="wp-block-heading">How We're Trading NVDA</h2>
I'm watching this corrective bounce very carefully for subtle clues which way it wants to break, but it's a fragile position for bulls while inside this corrective structure. Flows haven't shown a major bias yet, so I think the best thing is to stay put and look for conviction in the option flows and a break of the corrective structure.
I'll share our live trade ideas in real time with our members of the <a href="https://www.benzinga.com/premium/ideas/benzinga-options-school-webinar">Benzinga Option School</a> or <a href="https://www.benzinga.com/premium/ideas/trading-waves-997-offer/">Trading Waves</a>, so make sure to join and see how I'm trading it. I hope to see you there soon.

Opinion

Should You Buy This Nvidia Dip?

President Trump Says Spoke With Ukraine's Zelenskiy About Meeting On Friday In Munich To Be Led By Vice President Vance And Secretary Of State Rubio

Barrington Research analyst Gary Prestopino maintains Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) with a Outperform and raises the price target from $12 to $14.

Price Target

Analyst Ratings

CTLP

Barrington Research Maintains Outperform on Cantaloupe, Raises Price Target to $14

Ameriprise Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) short percent of float has fallen 5.19% since its last report. The company recently reported that it has 1.06 million shares sold short, which is 1.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ameriprise Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739384121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ameriprise Finl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ameriprise Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ameriprise Finl's peer group average for short interest as a percentage of float is 3.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(AMP) - Analyzing Ameriprise Finl's Short Interest

WR Berkley's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) short percent of float has risen 40.99% since its last report. The company recently reported that it has 6.76 million shares sold short, which is 2.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>WR Berkley Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739384115_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for WR Berkley has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing WR Berkley's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, WR Berkley's peer group average for short interest as a percentage of float is 2.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into WR Berkley's Recent Short Interest

Dayforce's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) short percent of float has fallen 23.53% since its last report. The company recently reported that it has 7.60 million shares sold short, which is 7.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dayforce Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739384110_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dayforce has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dayforce's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dayforce's peer group average for short interest as a percentage of float is 4.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Dayforce's Recent Short Interest

Rumors

GTLB

Watching GitLab; Hearing Investors Business Daily SwingTrader Buys Stock

Zelman &amp; Assoc analyst Jesse Lederman downgrades Hovnanian Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) from Neutral to Underperform.

Downgrades

Zelman & Assoc Downgrades Hovnanian Enterprises to Underperform

Morgan Stanley analyst Toni Kaplan maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Overweight and raises the price target from $595 to $600.

SPGI

Morgan Stanley Maintains Overweight on S&P Global, Raises Price Target to $600

Morgan Stanley analyst Keith Weiss maintains Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) with a Overweight and raises the price target from $126 to $144.

SHOP

Morgan Stanley Maintains Overweight on Shopify, Raises Price Target to $144

American International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) shares are trading lower today. On Tuesday, the company reported that the fourth quarter adjusted EPS of&nbsp;$1.30&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640648/aig-reports-outstanding-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">exceeded the consensus of $1.23</a>.
Piper Sandler analyst Paul Newsome writes that results came in above consensus but slightly below his estimates due to weaker <a target="_blank" href="https://www.benzinga.com/quote/aig/analyst-ratings" rel="noreferrer noopener">underwriting results and higher expenses</a>.
However, catastrophe losses were in line with his expectations and better than consensus, adds the analyst.
Notably, he notes that AIG reported a 92.5% combined ratio, better than consensus (93.3%) but slightly above his estimate of 91.5%.
Despite some segment noise, the company avoided broader casualty issues, adds the analyst.
Overall, Newsome says investors will view the results as better than expected.
Keefe, Bruyette &amp; Woods analyst Meyer Shields notes that AIG&#8217;s fourth-quarter operating EPS beat their $1.09 estimate, led by stronger core and catastrophe loss ratios, reserve releases and investment income, partially offset by higher expenses and taxes.
The analyst expects shares to gain on the EPS beat and reaffirmed the 10%+ ROE target for 2025, though gains may be tempered by a higher-than-expected expense ratio.
Investors can gain exposure to the stock via Invesco KBW Property &amp; Casualty Insurance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWP#NASDAQ">KBWP</a>) and iShares U.S. Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAK#NYSE">IAK</a>).
Price Action: AIG shares are down 1.49% at $74.81 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42933396/californias-10-trillion-property-market-faces-unprecedented-threat-from-wildfires" target="_blank" rel="noreferrer noopener">California&#8217;s $10 Trillion Property Market Faces Unprecedented Threat From Wildfires</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

iShares Dow Jones US Insurance Index Fund

KBWP

Analysts See AIG's Q4 As Positive, But Expense Ratio Limits Stock Gains

Morgan Stanley analyst Joshua Pokrzywinski maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $335 to $345.

Morgan Stanley Maintains Overweight on Rockwell Automation, Raises Price Target to $345

Federal Reserve

Fed's Goolsbee Says If We Got Multiple Months Like This (On CPI Inflation, Then The Job Is Clearly Not Done)

Morgan Stanley analyst Alex Poon maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Overweight and raises the price target from $108 to $117.

NTES

Morgan Stanley Maintains Overweight on NetEase, Raises Price Target to $117

Morgan Stanley analyst Sanjit Singh maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Equal-Weight and raises the price target from $30 to $32.

CFLT

Morgan Stanley Maintains Equal-Weight on Confluent, Raises Price Target to $32

Citigroup analyst Steven Enders maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Buy and lowers the price target from $73 to $70.

Citigroup Maintains Buy on BlackLine, Lowers Price Target to $70

MiNK Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming&nbsp;American Association for Cancer Research (AACR) IO Annual Meeting that will take place on&nbsp;February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (<a href="https://www.globenewswire.com/Tracker?data=t6txOKgp_MgEu4o8gN9EhC8-aPrKqm-f_6rS_BW7tVdkK00bmuNqJAGLdL_BAlX-0LUj7fqSq4pXWnarGuDxoySa8PvggMqTPCB8tryykvE=">NCT06251973</a>).

Biotech

General

INKT

MiNK Therapeutics To Present Updated Data From Phase 2 Study Testing AgenT-797 In Gastric Cancer At AACR IO Annual Meeting

<a href="https://www.globenewswire.com/Tracker?data=RRfz9O6r4fGsE9THQr6YofXWnwlfA4EcG2CrfxhZPi7GP2cKD-RstD59AmdT2vJk0ReK04g74dKxsKQ-a91FYdOC546yGDERB2Iuc5TXa1k=">Red Cat Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) ("Red Cat"), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, today announced it has entered into an agreement for up to $20 million and closed on the initial tranche of $16.5 Million in debt financing with The Lind Partners, a New York based institutional fund manager ("Lind"). Details of the agreement include:
<ul>
<li>Debt Financing convertible at $16.15 share price</li>
<li>Initial Tranche proceeds of $15 million</li>
<li>1 million warrants exercisable at $15.00 per share non cashless &nbsp;</li>
</ul>
Additionally, Red Cat has applied for $58 million in debt financing from the <a href="https://www.globenewswire.com/Tracker?data=31XzAh54dnto-MDxoRJEw-pG3ON3Z0v5FYpnv-NLc6smewtIUFSZEP0QdbDBtqJKE4vxZ-sqNfTD1jRhVS3jJExWx_7a49m7LDQowXZGAb1Cg_DH-fS4rUKqfBJKSk_Q3QwCsJmlziFWEa58e3COAg==">Department of Defense Office of Strategic Capital</a> (OSC). OSC implements strategies and partnerships to accelerate and scale private investment in critical supply chain technologies needed for national security. They have identified 14 critical technology areas vital to maintaining the United States' national security. These have been grouped into three categories as found in the 2023 National Defense Science and Technology Strategy.
<ul>
<li>Seed Areas of Emerging Opportunity</li>
<li>Effective Adoption Areas</li>
<li>Defense-Specific Areas &nbsp;</li>
</ul>
The investment is expected to provide Red Cat with the working capital needed to scale up production and the ongoing development of its Arachnid Family of Systems, which includes Black Widow&#x2122;, Edge 130, and a new line of FANG&#x2122; First-Person View (FPV) drones. The goal of the Family of Systems is to meet the needs of the U.S. Department of Defense and NATO Allies for drone systems that are low-cost, portable, field repairable, and recoverable.

Financing

RCAT

Red Cat Announces It Has Entered Into An Agreement For Up To $20M And Closed On The Initial Tranche Of $16.5M In Debt Financing With The Lind Partners, A New York Based Institutional Fund Manager

In the last three months, 7 analysts have published ratings on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $284.57, a high estimate of $301.00, and a low estimate of $255.00. Observing a 2.41% increase, the current average has risen from the previous average price target of $277.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383265_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$255.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$288.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$301.00</td>
<td>$288.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Humana's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Humana's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>About Humana</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Humana's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.26% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Humana's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.8% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio stands notably higher than the industry average, reaching 0.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Humana Stock: Analyst Perspectives (7 Ratings)

Barrington analyst Michael Petusky maintained a Hold rating on Lifecore Biomedical (LFCR – Research Report) today. The company's shares opened toda...

Barrington Keeps Their Hold Rating on Lifecore Biomedical (LFCR)

Lifecore (LFCR) Biomedical announced that it has entered into a sales agreement with a non-competitive buyer for the company's previously purchased...

Lifecore entered into sales agreement for 10-head isolator filler

Lifecore Biomedical to sell multi-purpose 10-head isolator filler

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Lifecore Biomedical (LFCR – Research Report). The company's sh...

Craig-Hallum Sticks to Their Buy Rating for Lifecore Biomedical (LFCR)

Barrington analyst Michael Petusky has maintained their neutral stance on LFCR stock, giving a Hold rating on January 3. Michael Petusky's rating i...

Lifecore Biomedical's Strategic Asset Sale Supports Hold Rating Amid Leverage Concerns

In a regulatory filing, Lifecore (LFCR) disclosed that its CEO Paul Josephs bought 17K shares of common stock on January 8th in a total transaction...

Lifecore CEO buys $97.6K in common stock

Laughing Water Capital Q4 2024 Letter

Lifecore Biomedical, Inc. (($LFCR)) has held its Q2 earnings call. Read on for the main highlights of the call. Lifecore Biomedical, Inc. recently ...

Lifecore Biomedical's Earnings Call: Growth Amid Challenges

Summers Value Partners Q4 2024 Partner Letter

Arquitos Capital Management Q4 2024 Commentary

AAPL

AMZN

BVHMF

BVHMY

CCSI

CDMO

ELMD

ENDI

FNCH

GOOG

GOOGL

HUBS

INDV

ISRG

LQDA

MODV

MSFT

MSTR

NTPIF

PCOA

PINC

SPOK

THRY

TSLA

TTAN

UFPT

UTMD

VSTS

ZIMV

Press Releases

Lifecore Biomedical to Present at Stephens Annual Investment Conference

Lifecore Biomedical Hosts Virtual Investor Day

Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO

Health Care

Contracts

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025

Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

Lifecore Biomedical Announces Special Stockholder Meeting

Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference

Akoya Biosciences

Applied DNA Sciences, Inc. - Common Stock

Applied DNA Sciences

Atlantic International Corp. - Common Stock

Atlantic International

Bionano Genomics

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals

ChromaDex

Codexis

Champions Oncology

CryoPort

Harvard Bioscience

Standard BioTools

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

MaxCyte

Nautilus Biotechnology, Inc. - Common Stock

Nautilus Biotechnology

Inotiv

OmniAb

Singular Genomics Systems, Inc. - Common Stock

Singular Genomics Sys

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Rapid Micro Biosystems, Inc. - Class A Common Stock

Rapid Micro Biosystems

Seer

Alpha Teknova

Stephens & Co.

Craig-Hallum

미국 주식 선물이 금요일 아침 (현지 시간 기준) 상승하고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다:
<ul>
<li>진디엑스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)는 브라이언 디카이로(Bryan Dechairo)를 COO로 임명했다고 발표했다. 진디엑스 주식은 애프터 마켓에서 2.7% 하락하여 $77.46에 거래되었다.</li>
<li>라이프코어 바이오메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>)는 목요일 2분기 실적을 발표했으며, 예상보다 나은 결과를 기록했다. 이 회사는 주당 25센트의 분기 손실을 보고했으며, 시장 예상치인 29센트의 손실보다 양호한 결과이다. 또한, 이 회사는 3,260만 달러의 분기 매출을 보고했으며, 이는 애널리스트 컨센서스 예상인 2,975만 달러를 초과한 수치이다. 라이프코어 바이오메디컬 주식은 애프터 마켓에서 5.3% 상승하여 $7.01에 거래되었다.</li>
<li>SPS 커머스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>)는 카본6 테크놀로지스(Carbon6 Technologies Inc.)를 인수하기로 합의했다. SPS 커머스 주식은 목요일에 0.6% 하락하여 $182.81에 거래되었다.</li>
</ul>
프리마켓 보도를 확인하려면 <a href="https://www.benzinga.com/premarket/">여기</a>를 클릭하세요.
<ul>
<li>리소스 커넥션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>)는 2분기 실적이 긍정적이라고 발표했다. 이 회사는 주당 18센트의 분기 이익과 1억 4,560만 달러의 매출을 보고했다. 리소스 커넥션 주식은 애프터 마켓에서 3.2% 상승하여 $9.00에 거래되었다.</li>
<li>UDR(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>)는 마이크 레이시(Mike Lacy)를 COO로 승진시키고 새로운 CFO를 채용하기 위한 임원 검색 프로세스를 시작할 계획이라고 발표했다. UDR 주식은 목요일에 2% 하락하여 $42.53에 거래되었다.</li>
<li></li>
</ul>
다음도 확인해 보세요: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">애큐티브랜즈 주식으로 1분기 실적 발표 전 매달 $500를 버는 방법</a></li>
</ul>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

목요일 아침 (현지 시간 기준) 미국 주식 선물이 상승함에 따라, 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다:
<ul>
<li>월스트리트는 리소스 커넥션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>)이 시장 마감 후에 1억 3,702만 달러의 매출을 보고할 것으로 예상하고 있다. 이에 따라 리소스 커넥션 주식은 시간외 거래에서 2% 상승한 8.70달러로 거래되었다.</li>
<li>니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)는 12월에 31,138대의 차량을 인도하여 전년 대비 72.9% 증가했다고 발표했다. 2024년 전체 인도량은 전년 대비 38.7% 증가한 221,970대에 달했다. 니오의 주식은 시간외 거래에서 0.9% 상승한 4.3995달러로 거래되었다.</li>
<li>애널리스트들은 라이프코어 바이오메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>)가 주당 30센트의 분기 손실을 기록하고, 매출은 2,975만 달러에 이를 것으로 예상하고 있다. 이 회사는 시장 종료 후에 실적을 발표할 예정이다. 라이프코어 바이오메디컬의 주식은 시간외 거래에서 2.6% 상승한 7.62달러로 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하세요.
<ul>
<li>리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)는 수요일에 12월에 58,513대를 인도하여 전년 대비 16.2% 증가, 11월의 48,740대 대비 20% 증가했다고 발표했다. 리 오토의 주식은 시간외 거래에서 0.4% 상승한 24.08달러로 거래되었다.</li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)은 12월 인도량이 증가했다고 보고했다. 이 회사는 12월에 36,695대를 인도하여 전년 대비 82%, 11월 대비 19% 증가했다. 2024년 전체적으로 샤오펑은 190,068대의 전기차를 인도하여 전년 대비 34% 증가했다. 샤오펑 주식은 시간외 거래에서 0.6% 상승한 11.89달러로 거래되었다.</li>
</ul>
다음 내용을 확인하세요:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42740135/how-to-earn-500-a-month-from-alphabet-stock">알파벳 주식으로 매달 500달러를 버는 방법</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포와 탐욕 지수가 전체 공포 수준이 약간 완화되었음을 보여주었지만, 이 지수는 화요일에 여전히 &#8220;공포&#8221; 구역에 머물렀다.
미국 주식은 화요일에 하락세로 마감했으며, 나스닥 종합지수는 세션 중 약 175포인트 하락했다.
주요 지수들이 연말 마지막 거래일에 하락세로 마감했지만, 여전히 2024년에 상승세를 기록했다. S&amp;P 500은 2024년에 23.31% 급등했으며, 2023년에는 24.2% 상승을 기록했다. 한편, 다우는 지난해 12.88% 상승했으며, 나스닥은 28.64%로 더 뛰어난 성과를 보였다.
엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 주가는 지난해 171% 급등하였고, 2024년에는 새로운 최고가를 기록했다. 뉴욕 주식시장은 수요일에 신정으로 휴장하였다.
경제 데이터 측면에서 S&amp;P 코어로직 케이스-실러 주택 가격 지수는 10월에 전년 대비 4.2% 상승하여 9월의 4.6% 증가 및 시장 예상치인 4.1% 상승을 하회했다. 이 FHFA 주택 가격 지수는 10월에 0.4% 상승하여 시장 예상치인 0.5% 증가를 하회했다. 텍사스의 서비스 부문에 대한 달라스 연방은행 일반 사업 활동 지수는 12월에 9.6으로 하락하여 11월의 9.8에서 하락했다.
S&amp;P 500의 대부분 섹터는 긍정적인 마감세를 보였고, 에너지, 원자재 및 부동산 주식이 가장 큰 상승폭을 기록했다. 그러나 소비재와 정보기술 주식은 전체 시장 추세에 반하여 하락세로 마감했다.
다우존스는 화요일에 약 30포인트 하락하여 42,544.22로 마감했다. S&amp;P 500은 0.43% 하락하여 5,881.63으로 마감했고, 나스닥 종합지수는 화요일 세션에서 0.90% 하락하여 19,310.79로 마감되었다.
투자자들은 오늘 리소스 커넥션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>)와 라이프코어 바이오메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>)의 실적 발표를 기다리고 있다.
CNN 비즈니스 공포와 탐욕 지수란?
현재 27.9의 수치를 기록한 이 지수는 화요일에 &#8220;공포&#8221; 구역에 머물렀으며, 이전 수치는 27.1이었다.
공포와 탐욕 지수는 현재 시장 심리를 측정한 것이다. 높은 공포는 주가에 압력을 가하고, 높은 탐욕은 그 반대의 효과를 미친다는 전제에 기반한다. 이 지수는 7개의 동등 가중 지표를 기반으로 계산된다. 지수는 0에서 100까지의 범위를 가지며, 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42740135/how-to-earn-500-a-month-from-alphabet-stock">알파벳 주식으로 한 달에 500달러를 버는 방법</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

2024년 S&P 500 지수 23% 급등, 그러나 탐욕 지수는 '공포' 지역에 머물러

금요일 오전 (현지 시간 기준) 미국 주가 지수 선물이 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 아포지 엔터프라이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>)가 분기 이익을 주당 1.23달러, 매출 3억 3,529만 달러로 예상하고 있다. 아포지의 주식은 애프터 마켓에서 0.1% 상승하여 68.50달러에 거래되었다.
2. 스마트 샌드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SND#NASDAQ">SND</a>)는 주당 10센트의 특별 현금 배당금을 선언하고, 1천만 달러의 자사주 매입을 승인했다. 스마트 샌드의 주식은 애프터 마켓에서 14% 급등하여 2.28달러에 거래되었다.
3. 애널리스트들은 라이프코어 바이오메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>)가 최신 분기에 주당 47센트의 분기 손실과 매출 2,318만 달러를 기록할 것으로 예상하고 있다. 이 회사는 시장 마감 후에 실적을 발표할 예정이다. 라이프코어 바이오메디컬의 주식은 목요일에 5.3% 하락하여 4.7050달러에 거래를 마쳤다.
프리마켓 보도를 <a href="https://www.benzinga.com/premarket/">여기에서 확인하세요</a>.
4. 마틴 미드스트림 파트너스 L.P.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMLP#NASDAQ">MMLP</a>)는 마틴 리소스 매니지먼트(Martin Resource Management)에 인수되기로 합의했다. 마틴 미드스트림 파트너스의 주식은 애프터 마켓에서 9.7% 급등하여 3.95달러에 거래되었다.
5. 에이지이글 에어리어 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>)는 보통주 1주를 50주로 병합하는 주식 역분할을 발표했다. 에이지이글 에어리어 시스템즈의 주식은 애프터 마켓에서 5.4% 하락하여 0.1150달러에 거래되었다.
이것도 확인하세요: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41172520/wall-streets-most-accurate-analysts-spotlight-on-3-defensive-stocks-delivering-high-dividend-yields">월스트리트의 가장 정확한 애널리스트들이 배당 수익률이 높은 방어주 3종목을 주목</a></li>
</ul>
사진 제공: Shutterstock

Comments

Lifecore Biomedical

뉴스

에 대한 최신 뉴스 Lifecore Biomedical (NASDAQ:LFCR) 주식

금요일, 1월 03, 2025

목요일, 1월 02, 2025

금요일, 10월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌